Skip to main content

DIMA Biotech

DIMA_Biotech

DIMA Biotechnology Ltd. is a biotech company focusing on preclinical R&D products and services for druggable targets. They plan to complete the preparation of lead antibody molecules for all druggable targets in the next 3-5 years. DIMA Biotech provides multiple pre-prepared lead antibody molecules for each target to help pharmaceutical companies skip the tedious steps of monoclonal antibody platform establishment and lead molecule screening. Therefore,  companies can  have more time to focus on the biological mechanism and developability study of drug targets, thus accelerating the process of new drug R&D.

Over the years, DIMA Biotech has been deeply engaged in developing and optimizing the underlying technology platforms for preclinical research. Currently, they have established two independently developed core technology platforms:

Single/multiple transmembrane protein eukaryotic expression, preparation and purification platforms, apply mammalian cell expression systems, provide ECD or full-length membrane protein products closest to native conformation and functional validation. In addition, DIMA Biotech has developed five major functional full-length transmembrane protein preparation systems, including Membrane Nanoparticle (MNP), Virus-Like Particle (VLP), Exosome (EXO), Detergent and Synthetic Nanodisc. Thousands of drug target protein products are in stock. 
DimAb® High-throughput single B-cell lead antibody molecule discovery platform. DIMA Biotech has completed the preparation and screening of lead antibody molecules against more than 200 drug targets by this platform in just two years. Moreover, they have formed strategic partnerships with several international pharmaceutical enterprises and licensed several drug target molecules. DIMA’s preclinical development strength is widely recognized by the industry. 


www.dimabio.com

The prices are on request! Contact Us by e-mail info@sobekbio.com

Human IL-29 (C-10His) Protein PME30045



The add to cart button will appear once you select the values above

Specifications

50µg

Alternative names:

Interferon lambda-1;IFN-lambda-1;Cytokine Zcyto21;Interleukin-29;IL-29;IFNL1;IL29;ZCYTO21

Description:

Recombinant Human Interferon Lambda-1 is produced by our Mammalian expression system and the target gene encoding Gly20-Thr200 is expressed with a 10His tag at the C-terminus.

Background:

Interleukin-29 (IL-29) is a secreted protein which belongs to the IL-28/IL-29 family. IL-29 is a cytokine with immunomodulatory activity. IL-29 is highly similar in amino acid sequence to the IL-28. IL-28 and IL-29 are induced by viral infection and showed antiviral activity. IL-28 and IL-29 interacted with a heterodimeric class II cytokine receptor that consisted of IL-10 receptor beta (IL-10R beta) and an orphan class II receptor chain, designated IL-28R alpha. IL-29 plays an important role in host defenses against microbes and its gene is highly upregulated in cells infected with viruses. IL-29 may play a role in antiviral immunity. IL-29 up-regulates MHC class I antigen expression. It is a Ligand for the heterodimeric class II cytokine receptor composed of IL10RB and IL28RA. The ligand/receptor complex seems to signal through the Jak-STAT pathway.

Molecular characterization:

Not available

Molecular weight:

21.4 KDa

Tag:

C-10×His Tag

Expression host:

HEK293

Target:

IL-29

Purity:

The purity of the protein is greater than 95% as determined by SDS-PAGE and Coomassie blue staining.

Formulation / Reconstitution:

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

Storage:

Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.

More info:

Email info@sobekbio.com

Orders:

Email orders@sobekbio.com